Sacubitril/Valsartan

BreastfeedingPediatric

FDA APPROVAL DATE: 07/07/2015

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Aliskiren, Lithium, NSAIDs, Potassium-sparing diuretics

PREGNANCY CATEGORY: N/A
Can cause fetal harm

Contraindicated in patients with a history of angioedema related to previous therapy with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker.

See also separate profile for valsartan.

FETAL TOXICITY

See full prescribing information for complete boxed warning.

Our database has 43 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
OCULAR
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of sacubitril/valsartan in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 01/31/2017

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric